ProQR Announces Planned Changes to Board Composition
MWN-AI** Summary
ProQR Therapeutics N.V., a clinical-stage biotechnology firm recognized for its innovative RNA therapies, has announced planned changes to its Board of Directors ahead of its next Annual General Meeting (AGM) in 2026. Co-founder Dinko Valerio and Board member Alison Lawton will step down as their terms come to a close. This decision aligns with ProQR's ongoing strategy to evolve alongside its clinical programs and reinforce its commitment to robust corporate governance and succession planning.
In a statement, James Shannon, MD, Chairperson of the Board, expressed gratitude for Valerio's leadership and Lawton's contributions, noting their significant influence in shaping the company’s vision and strategic direction. Chief Executive Officer Daniel A. de Boer echoed this sentiment, highlighting their invaluable insights while emphasizing the importance of the Board's diverse expertise in driving ProQR's mission forward.
To ensure effective governance and to continually adapt to its developmental needs, ProQR engages an executive search firm to identify prospective new Board members. This commitment to evolving Board composition has already seen the appointment of two new members in the past three years.
ProQR is renowned for its proprietary Axiomer™ RNA editing technology, which aims to create a new class of medicines targeting various diseases through precise RNA modifications. The platform utilizes the human cell's own machinery, ADAR, to enact subtle changes in RNA sequences, potentially correcting disease-causing mutations and altering protein expressions to enhance therapeutic efficacy.
As ProQR prepares for this transition, it underscores its dedication to long-term value creation while navigating the ever-evolving landscape of biotechnology and patient care. For additional information, stakeholders are encouraged to visit ProQR’s official website.
MWN-AI** Analysis
ProQR Therapeutics N.V. (Nasdaq: PRQR) recently announced planned changes to its Board composition, which are significant as the company advances its clinical programs. Understanding these changes is critical for investors looking to navigate ProQR's future performance.
The departure of co-founder Dinko Valerio and board member Alison Lawton reflects ProQR’s maturation as it positions itself for strategic growth. Their exit, while potentially unsettling, may herald the arrival of fresh perspectives that align with the company's evolving needs. An executive search firm has been engaged to secure new board members, underscoring ProQR’s commitment to strong corporate governance and long-term success.
Investors must note that ProQR is leveraging its proprietary Axiomer™ RNA editing technology, which presents a transformative approach to addressing genetic mutations that underlie various diseases. This innovative solution could pave the way for new medicinal classes, enhancing market interest in the company’s future pipeline.
However, prospective investors should also exercise caution. The biotechnology sector is inherently risky; ongoing challenges include the unpredictable nature of clinical trials, regulatory approvals, and potential market competition. ProQR's reliance on contract research organizations and manufacturers presents additional risks, particularly in maintaining a stable supply chain.
Given the context of the changing board and its implications, investors should weigh these developments against broader market conditions, including inflation, interest rates, and geopolitical tensions that could impact company performance.
In summary, while ProQR presents intriguing opportunities driven by innovative technology and strategic board refreshment, the associated risks must be carefully considered. Long-term investors should observe board changes closely, assessing their impact on ProQR’s strategic direction and clinical trial advancements before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company’s next Annual General Meeting (AGM) as their terms conclude.
The planned changes to ProQR’s Board composition at its 2026 AGM reflect the Company’s development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planning. An executive search firm has been engaged to assist ProQR in identifying candidates to be nominated to the Board to support long-term value creation for all its stakeholders.
“On behalf of the Board, I would like to sincerely thank Dinko for his leadership, which has played a central role in shaping ProQR’s vision and strategy, and Alison for her insight, dedication, and many valuable contributions to the Company during her tenure,” said James Shannon, MD, Chairperson of the Board of ProQR Therapeutics. “Their efforts have had a meaningful impact on ProQR, and we are deeply grateful for their expertise.”
“Dinko and Alison have brought meaningful perspective and presence to the Board,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “I have greatly appreciated their insights and contributions, and I look forward to continuing to work closely with the Board as we execute our strategy and advance our clinical and pipeline programs.”
As part of its ongoing governance practices, the Board regularly reviews its composition to ensure it maintains an appropriate balance of skills, experience, and perspectives to support ProQR’s long-term strategic objectives. This process has resulted in the appointment of two new Board members in the last three years.
About Axiomer™
ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “continue,” "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our business, technology and strategy, the anticipated timing and implementation of planned changes to the Board composition, expectations regarding corporate governance practices and long-term succession planning, and the continued advancement of our pipeline programs. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market, economic sanctions and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of participants and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical events and conflicts, high inflation, changing interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor and media contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
pkelleher@lifesciadvisors.com
FAQ**
How are ProQR Therapeutics N.V. PRQR's ongoing clinical programs influenced by the recent Board changes, and what strategies are in place to ensure continuity in leadership during this transition?
What role do Axiomer™ RNA editing technologies play in ProQR Therapeutics N.V. PRQR's mission to address unmet medical needs, especially in comparison to traditional therapies?
With Dinko Valerio and Alison Lawton stepping down from ProQR Therapeutics N.V. PRQR's Board, what specific skills and experiences is the executive search firm expected to seek in their replacements?
How does ProQR Therapeutics N.V. PRQR plan to optimize its corporate governance practices in light of the upcoming changes, and what measures are in place to support long-term stakeholder value creation?
**MWN-AI FAQ is based on asking OpenAI questions about ProQR Therapeutics N.V. (NASDAQ: PRQR).
NASDAQ: PRQR
PRQR Trading
-3.67% G/L:
$1.835 Last:
171,163 Volume:
$1.88 Open:
